The IDM - a cross-faculty, multidisciplinary postgraduate health research institute
Based on the UCT Faculty of Health Sciences campus in a 7,100 sqm state-of-the-art facility, we operate in the fields of infectious diseases and molecular medicine.
Clinical research relevant to the needs of Africa's people
The IDM influences health policy and practice by translating our scientific discoveries and applying them in various communities; community relationships and trust are critical.
Capacity building in the IDM
The largest research entity at UCT, the IDM is a national leader in research and health sciences human capital development.
IDM driving world class research
We conduct research at the laboratory-clinic-community interface by engaging a wide range of scientific and clinical disciplines; with 62 consortia linking us with 183 institutions in 22 African countries and 24 countries beyond.
University accredited research institute - Tackling diseases of importance in Africa - Developing people - Impacting health policy and practice
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town's (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduations ceremony on Saturday, 13 April.
Seven young University of Cape Town (UCT) scholars are among the inaugural 2019 cohort of Future Leaders – African Independent Research (FLAIR) Fellows. FLAIR Fellowships are awarded to talented African early-career researchers who have the potential to become leaders in their fields.
The University of Cape Town’s (UCT) Institute of Infectious Disease and Molecular Medicine (IDM) is based within the Faculty of Health Sciences (FHS). The Institute is a leading research centre on infectious disease in Africa. Speaking to the IDM’s positionality, Director, Professor Valerie Mizrahi says: “Unfortunately, we have a high burden of TB in this country and Cape Town is a heavily TB-burdened city, with high rates of HIV co-infection. However, we have a strong group of TB researchers in the IDM and elsewhere in the University. Our research groups have established outstanding clinical and laboratory capabilities for investigating new ways to intervene in TB by working at the intersection of the laboratory, clinic, and community. We are able to bring many disciplines to bear on this problem.”
Professor Ed Rybicki, the Director of the Biopharming Research Unit of the University of Cape Town’s (UCT’s) Molecular and Cell Biology Department, and member of the Institute of Infectious Disease and Molecular Medicine (IDM) has received an award which he says, acknowledges their long history in creating intellectual property (IP) at UCT.